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Abstract
Background: Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term 
outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact 
on disease-specific (DSS) and overall survival (OS).
Methods: The Surveillance, Epidemiology, and End Results (SEER) registry was queried for patients diagnosed with DCIS 
from 1991 to 2010. Treatment pattern trends were analyzed using Cochran-Armitage trend test. Survival analyses were 
performed using inverse probability weights (IPW)–adjusted competing risk analyses for DSS and Cox proportional hazard 
regression for OS. All tests performed were two-sided.
Results: One hundred twenty-one thousand and eighty DCIS patients were identified. The greatest proportion of patients 
was treated with lumpectomy and radiation therapy (43.0%), followed by lumpectomy alone (26.5%) and unilateral (23.8%) or 
bilateral mastectomy (4.5%) with significant shifts over time. The rate of sentinel lymph node biopsy increased from 9.7% to 
67.1% for mastectomy and from 1.4% to 17.8% for lumpectomy. Compared with mastectomy, OS was higher for lumpectomy 
with radiation (hazard ratio [HR] = 0.79, 95% confidence interval [CI] = 0.76 to 0.83, P < .001) and lower for lumpectomy alone 
(HR = 1.17, 95% CI = 1.13 to 1.23, P < .001). IPW-adjusted ten-year DSS was highest in lumpectomy with XRT (98.9%), followed 
by mastectomy (98.5%), and lumpectomy alone (98.4%).
Conclusions: We identified substantial shifts in treatment patterns for DCIS from 1991 to 2010. When outcomes between 
locoregional treatment options were compared, we observed greater differences in OS than DSS, likely reflecting both a 
prevailing patient selection bias as well as clinically negligible differences in breast cancer outcomes between groups.
Ductal carcinoma in situ (DCIS) of the breast is a clonal prolifera-
tion of cells that appear morphologically malignant by micros-
copy but are contained within the lumen of the mammary ducts 
by the basement membrane. DCIS is commonly identified by 
microcalcifications on mammography, with detection by pal-
pation accounting for less than 10% of cases (1). The incidence 
of DCIS has increased in parallel with the widespread adoption 
of mammography for breast cancer screening; while DCIS was 
rarely diagnosed prior to 1980, it currently accounts for over 20% 
of all new breast cancer diagnoses in the United States, with 
more than 60 000 new cases annually (2,3).
DCIS is widely considered to be a nonobligate precursor 
lesion of invasive ductal breast cancers. However, reliable prog-
nostic markers to identify those DCIS likely to progress to inva-
sive cancer remain elusive. Estimates of the proportion of DCIS 
that progress to invasive cancer vary widely, but studies indi-
cate that 20% to 30% of DCIS may progress at long-term follow 
up without definitive treatment (4–6). Because of this, detection 
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and treatment of DCIS is routinely recommended in an effort to 
reduce long-term breast cancer–specific mortality.
Tremendous variations in DCIS treatment patterns exist (7). 
Current National Comprehensive Cancer Network (NCCN) rec-
ommended treatment options include mastectomy, lumpec-
tomy with radiation, or lumpectomy alone with the potential 
addition of tamoxifen for hormone receptor–positive DCIS. 
Randomized trials indicate that lumpectomy with radiation 
therapy results in lower rates of DCIS recurrence but were 
underpowered to detect a difference in overall or breast cancer–
specific survival (4,8). Moreover, there are few data to indicate 
the magnitude of benefit to be derived from the currently rec-
ommended treatments compared with no treatment. Long-term 
active surveillance in well-selected patients is a potential alter-
native to surgical management, but largely because of concerns 
about an increased risk of invasive cancer at the time of delayed 
surgical excision and the lack of tools to predict which patients 
are most likely to progress, the acceptance rate for omission of 
surgery is very low (9,10). More precise estimates of the impact 
of contemporary treatment of DCIS on survival are needed to 
inform both future treatment recommendations and clinical tri-
als of alternative management strategies. We therefore designed 
a population-based study to analyze treatment trends and sur-
vival in a large cohort of patients with DCIS undergoing contem-
porary treatment.
Methods
We conducted a retrospective cohort study of patients diag-
nosed with ductal carcinoma in situ (DCIS) using the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) database (11). SEER is one of the largest validated cancer 
registries of the United States, representing almost 30% of all 
new cancer diagnoses per year. The SEER database was queried 
from 1991 to 2010 identifying female breast cancer patients age 
18 years or older with a behavior code in situ, excluding patients 
with ICD-O-3 codes of 8520/2 (lobular carcinoma in situ), 8522/2 
(intraductal and lobular in situ carcinoma), and 8720/2 (mela-
noma in situ). Patients without microscopic confirmation of the 
diagnosis, those identified at autopsy or on death certificate 
only or whose surgery was unknown, and patients for whom 
DCIS was not the first cancer diagnosis were also excluded from 
analysis.
SEER Treatment Variables and Covariates
Patient-specific variables included age (in quartiles), race (white, 
black, others/unknown), Hispanic origin, marital status (mar-
ried, not married, unknown), place of residence (rural, small 
urban, large urban), census tract based high school education 
(quartiles), and census tract based median household income 
(quartiles). Tumor-specific variables included: grade (low, inter-
mediate, high, unknown), tumor size (≤15 mm, 16–40 mm, 
>40 mm, unknown), estrogen receptor (ER) status (positive, 
negative, unknown), progesterone receptor (PR) status (positive, 
negative, unknown), and number of lymph node examinations 
(none, 1–4 categorized as sentinel lymph node biopsy [SLNB], ≥5 
categorized as axillary dissection [ALND]). Treatment charac-
teristics included surgery (none, lumpectomy, unilateral mas-
tectomy, bilateral mastectomy) and radiation therapy (yes, no). 
Systemic hormonal therapy was not reliably collected in SEER 
and was thus not included in the analysis. Patients age 91 years 
or older were recoded to age 90  years to fulfill HIPAA privacy 
regulations. The number of SEER registries increased over time; 
1991: nine registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, 
New Mexico, San Francisco, Seattle, Utah); 1992–1999: 13 regis-
tries (SEER 9 plus Alaska Natives, Los Angeles, Rural Georgia, San 
Jose-Monterey); after 2000: 18 registries (SEER 13 plus California, 
Greater Georgia, Kentucky, Louisiana, New Jersey).
Cause of death was based on SEER-attributed primary cause of 
death, categorized as breast cancer, other malignant disease, cardi-
ovascular disease, pulmonary disease, infectious disease, diabetes 
mellitus, and others/unknown. We grouped patients into five treat-
ment categories: no treatment, lumpectomy without radiation, 
lumpectomy with XRT, unilateral mastectomy, and bilateral mas-
tectomy excluding patients with other or unknown treatments.
Statistical Analysis
Demographic and tumor-related characteristics were compared 
between the different treatment groups using Pearson’s Chi-
square test for categorical (counts, percentage) and analysis of 
variance for continuous (mean+/-standard deviation) variables. 
To assess treatment changes over time, the Cochrane Armitage 
trend test was used. Subset analyses were performed to assess 
changes among patient characteristics in use of radiation after 
lumpectomy; trends within specific SEER registries were displayed 
using heat maps. For the purpose of survival analysis, we a priori 
restricted the analysis to locoregional treatments recommended 
for DCIS according to NCCN treatment guidelines: mastectomy 
(uni- or bilateral), lumpectomy with XRT, and lumpectomy alone. 
Cox proportional hazard regression analysis and competing risk 
survival models were used to assess overall (OS) and disease-spe-
cific survival (DSS), respectively. Patients lost to follow-up were 
right censored in the survival analysis. Because the treatment 
assignment for those patients was not random, multivariable 
analysis as well as inverse probability weighting (IPW) based on 
propensity scores was applied to adjust for potential confounding 
by indication (covariates: age, race, hispanic origin, marital status, 
place of residence, laterality, tumor grade, tumor size, ER status, 
PR status, high school education and household income level, 
and year of diagnosis) (Supplementary Table 1, available online) 
(12). This method aims to reduce effect of treatment selection, 
creating a pseudo-randomized study design based on all meas-
ured potential confounders in the dataset (12). The effects of 
individual variables on DSS and OS with and without weighting 
were calculated. To assess whether five-year DSS changed over 
time, we included year of diagnosis as predictor to the unad-
justed and multivariable-adjusted competing risk model. Further, 
IPW-adjusted survival curves were drawn after generalization of 
the method described by Cole et al. (13), and these IPW-adjusted 
curves were compared using the log-rank test. Additional strati-
fied analyses were performed using three age groups (age 18–49 
years, 50–69 years, and ≥70 years).
All statistical analyses were performed using STATA/SE ver-
sion 13.1 (Stata Corporation, College Station, TX) or SAS version 9.2 
(SAS Institute, Inc, Cary, NC). All P values were calculated as two-
sided, with statistical significance declared for P values below .05.
Results
Trends in DCIS Treatment
We identified 121 080 patients with DCIS who met the eligibility 
criteria. The largest proportion of patients underwent lumpec-
tomy with XRT (43.0%), followed by lumpectomy alone (26.5%), 
unilateral mastectomy (23.8%), bilateral mastectomy (4.5%), 
and no surgical treatment (2.3%) (Table 1). Patients undergoing 
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Table 1. Patient characteristics of SEER cohort diagnosed with DCIS* from 1991–2010 (n = 121 080 patients)*
Characteristic
No surgery or  
radiation therapy
Lumpectomy without 
radiation therapy
Lumpectomy with  
radiation therapy
Unilateral  
mastectomy
Bilateral 
mastectomy
No. (%) No. (%) No. (%) No. (%) No. (%) P†
Number of patients 2782 (2.3) 32 076 (26.5) 52 026 (43.0) 28 779 (23.8) 5417 (4.5)
Age, y, mean (SD) 61.6 (14.5) 61.8 (13.4) 58.1 (11.4) 58.4 (13.0) 50.9 (10.5) <.001
Race
 White 1981 (71.2) 25 751 (80.3) 41 790 (80.3) 22 186 (77.1) 4736 (87.4)
 Black 357 (12.8) 3092 (9.6) 4960 (9.5) 3149 (10.9) 321 (5.9) <.001
 Other/unknown 444 (16.0) 3233 (10.1) 5276 (10.1) 3444 (12.0) 360 (6.7)
Hispanic
 Yes 264 (9.5) 2731 (8.5) 4071 (7.8) 2261 (7.9) 355 (6.6) <.001
 No 2518 (90.5) 29 345 (91.5) 47 955 (91.2) 26 518 (92.1) 5062 (93.5)
Married
 Yes 1116 (40.1) 17 645 (55.0) 33 193 (63.8) 17 608 (61.2) 3767 (69.5)
 No 1015 (36.5) 12 645 (39.4) 17 221 (33.1) 10 288 (35.8) 1480 (27.3) <.001
 Unknown 651 (23.4) 1786 (5.6) 1612 (3.1) 883 (3.1) 170 (3.1)
Laterality
 Left 1390 (50.0) 16 409 (51.2) 26 652 (51.2) 14 845 (51.6) 2740 (50.6)
 Right 1355 (48.7) 15 641 (48.8) 25 371 (48.8) 13 920 (48.4) 2674 (49.4) <.001
 Unknown/other 37 (1.3) 26 (0.1) 3 (0) 14 (0.1) 3 (0.1)
Tumor grade
 Low 304 (10.9) 4839 (15.1) 5299 (10.2) 2100 (7.3) 431 (8.0)
 Intermediate 769 (27.6) 10 562 (32.9) 16 362 (31.5) 7044 (24.5) 1677 (31.0)
 High 640 (23.0) 7100 (22.1) 19 387 (37.3) 11 293 (39.2) 2500 (46.2) <.001
 Unknown 1069 (38.4) 9575 (29.9) 10 978 (21.1) 8342 (29.0) 809 (14.9)
Tumor size, mm
 ≤15 596 (21.4) 17 839 (55.6) 29 214 (56.2) 10 140 (35.2) 2012 (37.1)
 16–40 153 (5.5) 3444 (10.7) 7899 (15.2) 6091 (21.2) 1202 (22.2) <.001
 >40 89 (3.2) 858 (2.7) 1289 (2.5) 3125 (10.9) 621 (11.5)
 Unknown 1944 (69.9) 9935 (31.0) 13 624 (26.2) 9423 (32.7) 1582 (29.2)
ER status
 Positive 729 (26.2) 10 852 (33.8) 24 356 (46.8) 9905 (34.4) 2806 (51.8)
 Negative 127 (4.6) 1604 (5.0) 4601 (8.8) 3172 (11.0) 645 (11.9) <.001
 Unknown 1926 (69.2) 19 620 (61.2) 23 069 (44.3) 15 702 (54.6) 1966 (36.3)
PR status
 Positive 602 (21.6) 9065 (28.3) 20 296 (39.0) 7959 (27.7) 2297 (42.4)
 Negative 191 (6.9) 2549 (8.0) 7076 (13.6) 4332 (15.1) 957 (17.7) <.001
 Unknown 1989 (71.5) 20 462 (63.8) 24 654 (47.4) 16 488 (57.3) 2163 (39.9)
Living
 Rural 21 (0.8) 255 (0.8) 481 (0.8) 323 (1.1) 51 (0.9)
 Urban small 910 (32.7) 9999 (31.2) 17 722 (34.1) 10 006 (34.8) 1783 (32.9) <.001
 Urban large 1840 (66.1) 21 764 (67.9) 33 781 (64.9) 18 387 (63.9) 3578 (66.1)
 Unknown 11 (0.4) 58 (0.2) 42 (0.1) 63 (0.2) 5 (0.1)
Less than high school grade, %, quartiles
 I (<14.72) 544 (19.6) 6882 (21.5) 13 727 (26.4) 6718 (23.3) 1519 (28.0)
 II (14.72–17.63) 700 (25.2) 8101 (25.3) 15 163 (29.2) 7236 (25.1) 1561 (28.8)
 III (17.64–24.41) 661 (23.8) 7355 (22.9) 11 295 (21.7) 7196 (25.0) 1077 (19.9) <.001
 IV (≥24.42) 871 (31.3) 9732 (30.3) 11 838 (22.8) 7628 (26.5) 1259 (23.2)
 Unknown 6 (0.2) 6 (0.0) 3 (0.0) 1 (0.0) 1 (0.0)
Median household income, $, quartiles
 I (<38.8) 645 (23.2) 8217 (25.6) 11 679 (22.5) 9264 (32.2) 894 (16.5)
 II (38.8–44.93) 817 (29.4) 8704 (27.1) 12 756 (24.5) 7065 (24.6) 1293 (23.9)
 III (44.94–53.16) 623 (22.4) 7164 (22.3) 13 909 (26.7) 6446 (22.4) 1491 (27.5) <.001
 IV (≥53.16) 691 (24.8) 7985 (24.9) 13 679 (26.3) 6003 (20.9) 1738 (32.1)
 Unknown 6 (0.2) 6 (0.0) 3 (0.0) 1 (0.0) 1 (0.0)
Year‡
 1991–1995 181 (1.6) 3435 (30.9) 3240 (29.1) 4261 (38.3) 0
 1996–2000 519 (2.4) 6487 (30.2) 8256 (38.5) 5841 (27.2) 359 (1.7) <.001
 2001–2005 892 (2.2) 11 198 (27.1) 18 161 (44.0) 9328 (22.6) 1674 (4.1)
 2006–2010 1190 (2.5) 10 956 (23.2) 22 369 (47.3) 9349 (19.8) 3384 (7.2)
Status
 Alive 2252 (81.0) 27 499 (85.7) 48 732 (93.7) 25 357 (88.1) 5308 (98.0)
 Dead breast 106 (3.8) 351 (1.1) 353 (0.7) 324 (1.1) 18 (0.3) <.001
 Dead other 424 (15.2) 4226 (13.2) 2941 (5.7) 3098 (10.8) 91 (1.7)
* DCIS = ductal carcinoma in situ; ER = estrogen receptor; PR = progesterone receptor.
† P values based on Pearson’s Chi-square test for categorical (counts, percentage) and analysis of variance for continuous (mean+/-standard deviation) variables.
‡ Numbers and row percentages.
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bilateral mastectomy were in the youngest age group and more 
likely to be white, married, and in the highest income catego-
ries. Among those who underwent surgery, women treated with 
lumpectomy alone were oldest, least likely to be married, and 
most likely to have low-grade DCIS.
Between 1991 and 2010, we observed a statistically signifi-
cant change in treatment patterns. The proportion of patients 
undergoing lumpectomy with XRT increased (24.2%-46.8%), as 
did those treated with bilateral mastectomy (0%-8.5%) and no 
treatment (1.2%-3.2%). In contrast, there was a statistically sig-
nificant reduction in the rate of unilateral mastectomy (44.9%-
19.3%) and lumpectomy alone (29.8%-22.3%, Ptrend < .001 for all 
groups) (Figure 1A).
Axillary management differed statistically significantly 
between patients undergoing mastectomy and those undergo-
ing lumpectomy. For patients undergoing mastectomy, SLNB 
0
10
20
30
40
50
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010
None
Lumpectomy
without XRT
Lumpectomy with XRT
Unilateral mastectomy
Bilateral mastectomy
0
20
40
60
80
100
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010
Mastectomy only
Mastectomy with SLNB
Mastectomy with ALND
Lumpectomy only
Lumpectomy with SLNB
Lumpectomy with ALND
99
99.2
99.4
99.6
99.8
100
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010
Lumpectomy with XRT
Lumpectomy without XRT
Mastectomy
All treatments
D
S
S
 5
-y
ea
r 
su
rv
iv
al
, %
R
at
e,
 %
R
at
e,
 %
Year of diagnosis
A
B
C
Figure 1. Time trends of treatment and survival among ductal carcinoma in situ (DCIS) patients diagnosed from 1991 to 2010. A) Trends of breast locoregional treat-
ment. B) Trends of axillary surgery procedures grouped by mastectomy and lumpectomy. C) Trend of five-year disease-specific survival overall and for patients under-
going mastectomy, lumpectomy with/without radiation therapy. 95% confidence interval provided for “All Treatments” only. ALND = axillary lymph node dissection 
(≥ 5 LNs), if no nodes were indicated, case coded as having had no lymph node surgery; DSS = disease-specific survival; LN = lymph node; SLNB = sentinel lymph node 
biopsy (1–4 LN); XRT = radiation therapy.
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increased from 9.7% to 67.1% and axillary dissections dropped 
from 62.9% to 15.3% (Ptrend < .001 for both comparisons). For 
patients undergoing lumpectomy, the rate of SLNB increased 
from 1.4% to 17.8% and the rate of axillary dissections decreased 
from 14.2% to 2.8% (Ptrend < .001 for both comparisons) (Figure 1B).
The increased use of adjuvant radiation after lumpectomy 
was observed among all patient groups (Table  2). Overall, the 
rate increased from 48.5% in 1991 to 1995 to 67.1% in 2006 to 
2010 (P < .001). Major differences in the rate of radiation use 
after lumpectomy were found among SEER registries. For the 
first time period (1991–1996), rates varied from 37.5% in Alaska 
to 65.7% in Hawaii (Figure 2). Major differences persisted during 
the last time period (2006–2010), with rates varying from 50.3% 
in Utah to 84.6% in Iowa.
Overall and Disease-Specific Survival
Survival analyses were performed on patients undergoing 
mastectomy (unilateral or bilateral), lumpectomy with XRT, 
and lumpectomy alone (n  =  118 298 patients). Median follow-
up for patients with DCIS was 71 months (interquartile range 
[IQR]  =  33–115). Ninety-seven point eight percent of patients 
age 49  years or younger at diagnosis were alive at their last 
follow-up, while 72.0% of patients older than 70 years were alive 
(Table 3).
Crude five- and 10-year OS for the cohort undergoing sur-
gery for DCIS were 95.0% and 85.9%, respectively. Overall sur-
vival was highest for patients undergoing lumpectomy with XRT 
(96.8% and 89.6%), followed by mastectomy (95.1% and 86.1%) 
and lumpectomy alone (92.3% and 80.6%, P < .001). Both unad-
justed and multivariable-adjusted analyses showed that com-
pared with patients undergoing mastectomy those undergoing 
lumpectomy with XRT had higher OS (Supplementary Table 2, 
available online). These findings were confirmed even after IPW-
adjustment (hazard ratio [HR]  =  0.79, 95% confidence interval 
[CI]  =  0.76 to 0.83, P < .001) (Supplementary Table  2, available 
online). Patients with lumpectomy alone had the highest risk 
of all-cause mortality (HR = 1.17, 95% CI = 1.13 to 1.23). In IPW-
adjusted analysis, older patients, blacks, nonmarried patients, 
and those with larger tumors and lower median household 
income showed worse OS compared with their counterparts.
Given that breast cancer mortality comprised a relatively 
small proportion of overall mortality, we analyzed competing 
causes of death in women stratified by age group and treatment 
(Table 3). In the overall cohort, breast cancer was identified as 
the cause of death in 9.2% of women. However, the predominant 
cause of mortality was attributed to cardiovascular disease, 
Table 2. Trends of patient characteristics undergoing lumpectomy with radiation therapy compared with lumpectomy alone*
Characteristic Number of patients who underwent lumpectomy with XRT (% of all lumpectomy patients) Ptrend
Year of diagnosis 1991–1995 1996–2000 2001–2005 2006–2010
Number of patients 3240 (48.5) 8256 (56.0) 18.161 (61.9) 22 369 (67.1) <.001
Age group, y
 18–49 1039 (56.5) 2319 (62.0) 4553 (65.2) 5419 (71.7) <.001
 50–58 795 (56.1) 2243 (61.5) 5133 (65.9) 6325 (71.1) <.001
 59–69 881 (51.1) 2124 (57.1) 5012 (65.3) 6750 (70.6) <.001
 70–90 525 (31.0) 1570 (43.3) 3463 (50.2) 3875 (53.0) <.001
Race
 White 2699 (48.9) 6696 (55.8) 14 799 (62.0) 17 596 (67.3) <.001
 Black 243 (44.6) 656 (52.6) 1679 (61.0) 2382 (67.9) <.001
 Other/unknown 298 (48.5) 904 (60.2) 1683 (61.7) 2391 (65.2) <.001
Hispanic
 Yes 171 (45.6) 502 (52.4) 1386 (60.3) 2012 (63.5) <.001
 No 3069 (48.7) 7754 (56.3) 16 775 (62.0) 20 357 (67.5) <.001
Married
 Yes 2112 (53.3) 5255 (59.4) 11 661 (65.0) 14 165 (70.5) <.001
 No 1050 (43.3) 2678 (51.4) 6086 (58.0) 7407 (63.1) <.001
 Unknown 78 (26.7) 323 (46.7) 414 (44.4) 797 (53.8) <.001
Median household income, $, quartiles
 I (<39.11) 2238 (47.5) 3288 (55.1) 3127 (64.9) 3738 (68.7) <.001
 II (39.39–45.09) 639 (55.7) 1821 (54.7) 4519 (57.4) 5408 (62.0) <.001
 III (45.20–54.10) 356 (44.6) 1872 (60.2) 5404 (66.1) 6483 (71.0) <.001
 IV (≥54.27) 7 (53.9) 1275 (54.4) 5111 (60.2) 6737 (67.3) <.001
 Unknown 0 0 0 3 (33.3)
Less than high school grade, %, quartiles
 I (<14.72) 692 (51.1) 1985 (58.7) 4791 (65.7) 6259 (73.0) <.001
 II (14.72–17.62) 498 (51.0) 1923 (61.4) 5059 (65.2) 6015 (68.8) <.001
 III (17.64–24.36) 1278 (49.7) 2482 (57.0) 4073 (60.5) 5130 (67.0) <.001
 IV (≥24.42) 772 (43.6) 1866 (48.2) 4238 (55.9) 4962 (59.4) <.001
 Unknown 0 0 0 3 (33.3)
Living
 Rural 16 (48.5) 79 (66.4) 162 (60.7) 224 (70.7) .003
 Urban small 995 (54.5) 2720 (61.2) 6226 (62.5) 7781 (67.7) <.001
 Urban large 2223 (46.3) 5451 (53.7) 11 759 (61.5) 14 348 (66.8) <.001
 Unknown 6 (54.6) 6 (24.0) 14 (46.7) 16 (47.1) .77
* XRT = radiation therapy.
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accounting for 33.0% of all deaths, followed by other malignan-
cies (22.2% of all deaths). In women 70 years or older at diag-
nosis, 40.2% of all deaths were from cardiovascular disease, 
compared with 5.4% from breast cancer.
IPW-adjusted five- and 10-year DSS for all patients were 
99.5% and 98.5%, respectively. Similar to our findings for OS, 
IPW-adjusted DSS was highest in the group that underwent 
lumpectomy with XRT (99.6% and 98.9%), followed by mastec-
tomy (99.5% and 98.5%) and lumpectomy alone (99.4% and 98.4%, 
P  =  .0089) (Figure  3). IPW-adjusted competing risk analysis for 
DSS revealed that patients undergoing lumpectomy with XRT 
had similar survival compared with mastectomy (HR = 0.89, 95% 
CI = 0.76 to 1.03), while patients undergoing lumpectomy alone 
showed increased breast cancer mortality compared with mas-
tectomy (HR = 1.18, 95% CI = 1.02 to 1.36) (Supplementary Table 3, 
available online). Based on these data, 200 patients would need 
to be treated with radiation after lumpectomy for each breast 
cancer death averted at 10  years. Multivariable-adjusted five-
year DSS statistically significantly improved over time overall 
(HR per one year increment  =  0.972, 95% CI  =  0.952 to 0.993) 
and for lumpectomy without radiation therapy (HR = 0.962, 95% 
CI = 0.928 to 0.0.996), while no such increase was found for mas-
tectomy (HR = 0.977, 95% CI = 0.943 to 1.012) or lumpectomy with 
radiation therapy (HR = 0.986, 95% CI = 0.951 to 1.023) (Figure 1C).
Figure 2. Adjuvant radiation rates per Surveillance, Epidemiology, and End Results (SEER) registry among patients undergoing lumpectomy: A) 1991–1995 (SEER 9 and 
13); B) 1996–2000 (SEER 13 and 18); C) 2001–2005 (SEER 18); D) 2006–2010 (SEER 18). Registries: SEER 9: Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Fran-
cisco, Seattle, Utah. SEER 13: SEER 9 plus Alaska Natives, Los Angeles, Rural Georgia, San Jose-Monterey. SEER 18: SEER 13 plus California, Greater Georgia, Kentucky, 
Louisiana, New Jersey. XRT = Radiation Therapy.
Table 3. Causes of mortality stratified by 3 age groups and 3 treatment groups*
Causes of death
Age group, y Treatment group
18–49
No. (%)
50–69
No. (%)
≥70
No. (%)
Mx
No. (%)
Lx - XRT
No. (%)
Lx + XRT
No. (%)
Number of patients 31 036 (26.2) 63 229 (53.5) 24 033 (20.3) 34 196 (28.9) 32 076 (27.1) 52 026 (44.0)
Alive at last follow-up 30 344 (97.8) 59 254 (93.7) 17 298 (72.0) 30 665 (89.7) 27 499 (85.7) 48 732 (93.7)
Cause of death, %
 Breast cancer 236 (34.1) 443 (11.1) 367 (5.4) 342 (9.7) 351 (7.7) 353 (10.7)
 Other malignant disease 180 (26.0) 1201 (30.2) 1152 (17.1) 731 (20.7) 916 (20.0) 886 (26.9)
 Cardiovascular disease 73 (10.5) 986 (24.8) 2708 (40.2) 1157 (32.8) 1681 (36.7) 929 (28.2)
 Pulmonary disease 5 (0.7) 232 (5.8) 351 (5.2) 182 (5.2) 267 (5.8) 139 (4.2)
 Infectious disease 18 (2.6) 127 (3.2) 249 (3.7) 120 (3.4) 162 (3.5) 112 (3.4)
 Diabetes mellitus 12 (1.7) 112 (2.8) 169 (2.5) 112 (3.2) 104 (2.3) 77 (2.3)
 Other/unknown 168 (24.3) 874 (22.0) 1739 (25.8) 887 (25.1) 1096 (23.9) 798 (24.2)
* Lx = lumpectomy; Mx = mastectomy; XRT = radiation therapy.
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For patients diagnosed younger than 50 years, breast cancer 
was identified as the cause of mortality for 236 deaths (34.1%) 
at a median of 84 months after diagnosis, while it accounted for 
443 deaths (11.1%) among patients age 50 to 69 years (median 
time to breast cancer death = 82 months) and 367 deaths (5.4%) 
among patients age 70 years and older (median time to breast 
cancer death  =  71  months) (Table  3). Age-stratified analyses 
were performed for both OS and DSS. IPW-adjusted analyses 
for patients age 18 to 49 years showed similar OS and DSS for 
lumpectomy with XRT, while it was worse for lumpectomy alone 
compared with mastectomy (Table 4). For patients age 50 to 69 
and older than 70 years, IPW-adjusted analysis showed better 
OS for lumpectomy with XRT and worse for lumpectomy alone. 
There was no difference in DSS in these age groups.
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Figure 3. Overall and breast cancer–specific survival by locoregional treatment, overall group, and stratified by three age groups based on inverse probability weight 
(IPW)–adjusted survival data. All P values based on IPW-adjusted, two-sided log-rank test. Left column, overall survival: A) entire cohort, B) 18–49 years, C) 50–69 years, 
D) ≥70 years. Right column, breast cancer–specific mortality: E) entire cohort, F) 18–49 years, G) 50–69 years, H) ≥70 years. XRT = Radiation Therapy.
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Discussion
The increased incidence of DCIS following widespread adop-
tion of mammographic screening has been well described 
(2,14). National efforts to promote screening and early detec-
tion have dramatically increased the rate of diagnosis of this 
disease, although the public health implications of DCIS treat-
ment remain poorly understood. Based on our study, only 2.3% 
of patients did not undergo surgery for DCIS; the majority of 
patients had treatment involving lumpectomy with or without 
radiation therapy, or mastectomy, with each treatment likely 
impacting long-term quality of life (15,16). Natural history stud-
ies support that only 20% to 30% of DCIS lesions managed with 
biopsy alone will eventually progress to invasive breast cancer; 
for other women with low risk of recurrence or progression, 
treatment may provide little benefit in DSS with clear risk of 
harm from treatment. Apart from the morbidity of surgery, seri-
ous albeit rare long-term complications may result from radia-
tion therapy. These include development of angiosarcomas, 
increased morbidity associated with heart and lung disease, rib 
fracture, lymphedema, and tissue necrosis and fibrosis (17–19). 
Identification of DCIS subtypes that are at high risk of inva-
sive progression would aid in weighing the risks of treatment 
against the benefits of therapy. Molecular risk stratification tools 
have been developed but are not yet in widespread use (20,21). 
Additional advances are urgently needed in order to provide 
both patients and providers actionable risk assessment based 
on potential for invasion (22).
In this study, we found a substantial shift in locoregional 
treatment patterns for DCIS. The use of lumpectomy with radia-
tion increased by almost 100%, whereas use of unilateral mas-
tectomy dropped by 60%. The bilateral mastectomy rate for DCIS 
increased from 0% to 8.5%, a trend likely driven by prophylactic 
contralateral mastectomy rather than by bilateral DCIS (23,24). 
Our analysis supports other studies, which have shown that 
compared with patients treated with lumpectomy and radiation 
those electing bilateral mastectomy were younger and more 
likely to be white and married with a higher median household 
income. In addition, when using mortality from causes other 
than breast cancer, the group undergoing bilateral mastectomy 
was least likely to die of non-breast cancer–related causes com-
pared with any other surgical treatment group (data not shown). 
Our results also show that in patients undergoing lumpec-
tomy, the use of adjuvant radiation therapy increased among 
all patient subgroups. Smaller differences were identified on a 
patient level. However, more striking differences in radiation 
use were found on a SEER registry level. While this variation in 
treatment pattern by region may in part be because of differ-
ences in ascertainment between regions, it confirms a recent 
finding based on Kaiser Permanent data where use of radiation 
therapy after breast-conserving therapy differed statistically 
significantly by location (25). Reasons for such geographical vari-
ation remain unclear and are of concern, as these data suggest 
that treatment decisions are much more strongly driven by the 
geography where the diagnosis was made, rather than by DCIS 
disease characteristics.
Table 4. Subgroup analysis of overall and breast cancer–specific survival, stratified by 3 age-groups (18–49 years, 50–69 years, ≥70 years)*
Age and 
treatment
Unadjusted Multivariable-adjusted IPW-adjusted IPW-adjusted survival rates
HR (95% CI) P HR (95% CI) P HR (95% CI) P 5-year 10-year
Overall survival
Age 18–49 y
 Mx Ref. Ref. Ref. 0.989 (0.988 to 0.991) 0.969 (0.966 to 0.971)
 Lx + XRT 0.85 (0.71 to 1.01) .06 0.91 (0.76 to 1.10) .33 0.89 (0.74 to 1.07) .21 0.993 (0.991 to 0.994) 0.975 (0.973 to 0.978)
 Lx - XRT 1.13 (0.94 to 1.37) .19 1.21 (0.99 to 1.47) .06 1.26 (1.06 to 1.50) .008 0.985 (0.983 to 0.986) 0.961 (0.958 to 0.964)
Age 50–69 y
 Mx Ref. Ref. Ref. 0.970 (0.968 to 0.971) 0.911 (0.907 to 0.914)
 Lx + XRT 0.83 (0.77 to 0.90) <.001 0.88 (0.81 to 0.96) .002 0.87 (0.80 to 0.94) <.001 0.976 (0.974 to 0.977) 0.925 (0.921 to 0.928)
 Lx - XRT 1.07 (0.99 to 1.16) .11 1.09 (1.00 to 1.19) .05 1.09 (1.01 to 1.17) .03 0.965 (0.963 to 0.966) 0.907 (0.904 to 0.910)
Age ≥70 y
 Mx Ref. Ref. Ref. 0.860 (0.855 to 0.865) 0.617 (0.608 to 0.625)
 Lx + XRT 0.70 (0.66 to 0.75) <.001 0.74 (0.70 to 0.79) <.001 0.75 (0.70 to 0.79) <.001 0.904 (0.900 to 0.908) 0.695 (0.687 to 0.703)
 Lx - XRT 1.18 (1.12 to 1.25) <.001 1.21 (1.14 to 1.28) <.001 1.22 (1.16 to 1.29) <.001 0.815 (0.810 to 0.820) 0.561 (0.552 to 0.569)
Breast cancer–specific survival
Age 18–49 y
 Mx Ref. Ref. Ref. 0.997 (0.996 to 0.998) 0.989 (0.987 to 0.990)
 Lx + XRT 0.83 (0.61 to 1.12) .60 1.04 (0.76 to 1.42) .82 1.02 (0.74 to 1.41) .92 0.998 (0.997 to 0.998) 0.992 (0.990 to 0.993)
 Lx - XRT 1.09 (0.79 to 1.50) .23 1.37 (0.98 to 1.92) .06 1.55 (1.16 to 2.09) .004 0.995 (0.994 to 0.996) 0.984 (0.982 to 0.986)
Age 50–69 y
 Mx Ref. Ref. Ref. 0.996 (0.996 to 0.997) 0.988 (0.987 to 0.989)
 Lx + XRT 0.85 (0.67 to 1.06) .15 0.94 (0.75 to 1.19) .60 0.90 (0.71 to 1.13) .37 0.997 (0.996 to 0.997) 0.991 (0.990 to 0.992)
 Lx - XRT 0.93 (0.72 to 1.18) .53 1.02 (0.79 to 1.31) .91 1.00 (0.79 to 1.26) .99 0.997 (0.996 to 0.997) 0.989 (0.988 to 0.990)
Age ≥70 y
 Mx Ref. Ref. Ref. 0.990 (0.988 to 0.991) 0.975 (0.972 to 0.978)
 Lx + XRT 0.81 (0.62 to 1.05) .11 0.92 (0.70 to 1.20) .52 0.84 (0.66 to 1.08) .18 0.992 (0.990 to 0.993) 0.978 (0.975 to 0.980)
 Lx - XRT 1.14 (0.90 to 1.44) .29 1.21 (0.95 to 1.55) .13 1.17 (0.92 to 1.48) .20 0.988 (0.987 to 0.990) 0.971 (0.967 to 0.974)
* Cox proportional hazard regression analysis for overall survival and competing risk survival models for breast cancer–specific survival were used (two-sided). Co-
variates for multivariable/IPW adjustment: age, race, Hispanic origin, marital status, place of residence, laterality, tumor grade, tumor size, estrogen receptor status, 
progesterone receptor status, high school education, household income level, and year of diagnosis. CI = confidence interval; HR = hazard ratio; Lx = lumpectomy; 
Mx = mastectomy; IPW = inverse probability weight; Ref. = referent; XRT = radiation therapy.
 at U
niversitaetsspital-B
ibliothek U
SB
 on February 14, 2016
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
9 of 10 | JNCI J Natl Cancer Inst, 2015, Vol. 107, No. 12
a
r
t
ic
le
a
r
t
ic
le
DCIS is a noninvasive diagnosis and, as such, has little pro-
pensity for lymphatic spread (26,27). However, axillary surgery 
continued to be employed in both lumpectomy and mastec-
tomy groups. We observed that in 2010, 60% of patients did not 
undergo surgical assessment of the axilla. The use of sentinel 
node biopsy for DCIS has increased markedly, reflecting a simi-
lar trend for invasive breast cancers (28). Concomitantly, there 
has been an encouraging reduction in the use of axillary node 
dissection. We observed that in 2010 71.6% of mastectomy pro-
cedures included sentinel lymph node biopsy. This is appropri-
ate, given an up to 20% upstaging rate following surgical excision 
of DCIS and the technical difficulty of accurately identifying the 
sentinel node after mastectomy (29,30). However, sentinel lymph 
node biopsy was observed in almost 20% of patients undergoing 
lumpectomy. The low prevalence of node involvement in the set-
ting of DCIS and minimal impact of lumpectomy on feasibility 
of subsequent axillary surgery supports a more restrained use 
of sentinel node biopsy with lumpectomy for DCIS. Moreover, 
15.3% of women undergoing mastectomy and 2.8% undergoing 
lumpectomy underwent axillary node dissection in 2010. Thus, 
the current rate of axillary surgery overall, and of axillary dis-
section specifically, remains higher than indicated based upon 
the recent American Society of Clinical Oncology clinical practice 
guidelines and represents both a source of concern as well as a 
target for further education (31). Despite the reduction in extent 
of surgery performing more lumpectomy over mastectomy and 
decline in axillary surgery rates, disease-specific survival statisti-
cally improved throughout the study period. However, the clinical 
relevance of this improvement is likely not clinically meaningful.
This is the largest population-based study to date assessing 
the association between locoregional treatment and survival 
outcomes in women with DCIS. SEER has long employed a con-
sistent algorithm to ascertain cause of death and to ensure that 
disease-specific survival is adjudicated as accurately as possible 
(11). Moreover, we applied advanced statistical methodology for 
retrospective data to account for known biases between treat-
ment groups. We found that overall survival was highly asso-
ciated with choice of treatment, even after IPW adjustment. In 
contrast, we observed that 10-year DSS differed by only 0.5% 
between the groups undergoing lumpectomy (98.4%) compared 
with lumpectomy with XRT (98.9%), with mastectomy resulting 
in essentially the same DSS as lumpectomy alone (98.5%), differ-
ences among treatment groups of an amount that might have 
very limited clinical impact but supporting that ultimately clini-
cal value should drive treatment decisions. Because of the very 
low disease-specific mortality, the statistically significant differ-
ences in OS between treatment groups were largely attributed 
to selection bias, likely based on comorbidities at presentation. 
In fact, when we used age at diagnosis as a proxy for comor-
bidity, breast cancer accounted for about one third of deaths in 
patients younger than age 50 years but only for 5.4% in patients 
age 70 or older. It has been shown that comorbidities in older 
women are responsible for many if not most of the deaths in 
breast cancer patients, a particularly important consideration 
for women diagnosed with DCIS given the even lower attendant 
mortality of this diagnosis (32). In contrast, given that one third 
of deaths in the youngest age group occurred because of breast 
cancer highlights the importance of aggressive treatment for 
those patients. Further characterization of patients who did not 
undergo surgical treatment of DCIS as well as detailed assess-
ment of which patients may most likely benefit from active 
surveillance are critical areas to pursue in future research as 
attention moves towards minimizing overtreatment for this 
disease.
While randomized trials clearly show the benefit of adjuvant 
radiation on local recurrence, we were unable to demonstrate 
an effect of radiation on DSS (33). The excellent overall disease-
specific outcome regardless of treatment raises the possibility 
that patients may derive little clinically meaningful benefit of 
treatment for DCIS in the presence of comorbidities, particularly 
if life expectancy does not exceed 10 years. This is highly rel-
evant for DCIS treatment because as in many other cancers the 
incidence rate increases, with age peaking around 74 years (2). 
Although our analysis does not provide information on survival 
related to watchful waiting or nonsurgical strategies, it does 
suggest a limited benefit from standard multimodality treat-
ment of DCIS among patients with important competing causes 
of mortality. Thus, we contend that less aggressive treatment 
for DCIS should be considered in select subsets of patients. The 
role of watchful waiting for DCIS must be further assessed but 
might follow the treatment strategies of contemporary prostate 
cancer treatment, where overall health and expected survival of 
patients play a crucial role, weighed against morbidity of treat-
ment (34). Observational or registry studies designed to address 
this issue would be of tremendous benefit.
As with all retrospective studies, outcomes such as overall 
and disease-specific survival must be interpreted with caution, 
particularly for a disease that rarely results in death. The present 
analysis suggests an important selection bias in favor of more 
fit patients undergoing the most invasive treatments, supported 
by our observation that the five-year OS differed statistically 
between treatment groups by as much as 4.5%, whereas the DSS 
only differed by 0.2%. This limits the ability to derive meaning-
ful associations between treatment, or indeed absence of treat-
ment, and disease-specific outcomes, although it does afford the 
opportunity to contextualize the contribution of DCIS treatment 
to overall health outcomes among different age groups. Despite 
availability of information on cause of death including breast 
cancer, it remains unclear whether the responsible tumor was 
de novo or a consequence of DCIS progression to invasive breast 
cancer. In addition, the relatively small number of patients for 
whom accurate systemic treatment data are available in SEER 
precludes the evaluation of adjuvant endocrine therapy on out-
comes, which will be important in future analyses as such data 
become available. Another key limitation in this, as in all other 
analyses using the SEER registry, is the absence of data with 
which to study the direct effects of baseline comorbidities, indi-
vidual treatment decision-making, surgical resection margin, 
or performance status on primary outcomes. It is also known 
that radiation therapy is often underreported in administrative 
datasets like SEER (35). This said, disease-specific survival differ-
ences could potentially be bigger than reported in this manu-
script, although very unlikely to change the results to a more 
clinically important degree. Finally, although the present analy-
sis evaluated the association of treatment on survival endpoints 
only, it is important to acknowledge that recurrence endpoints 
and impact on quality of life are also meaningful to patients and 
thus must be considered in future studies.
In summary, surgical treatment patterns for DCIS have 
evolved substantially between 1991 and 2010 in the United 
States, paralleling treatment trends in the management of inva-
sive breast cancer. The choice of locoregional treatment had a 
strikingly small impact on breast cancer–specific survival, call-
ing for a more thoughtful and restrained treatment approach 
for this disease. Consideration of an individual’s health and life 
expectancy as well as implementation of less invasive treat-
ment options, including active surveillance in thoughtfully 
selected patients, could yield the greatest benefit and minimize 
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treatment-related harms for future patients diagnosed with 
DCIS.
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